Summary:
- Mavacamten is a new drug that has been approved by the FDA to treat a serious heart condition called hypertrophic cardiomyopathy (HCM).
- HCM is a genetic disorder that causes the heart muscle to thicken, making it harder for the heart to pump blood effectively. Mavacamten works by reducing the excessive contraction of the heart muscle, which helps improve the heart's ability to pump blood.
- Clinical trials have shown that Mavacamten can significantly improve symptoms and quality of life for people with HCM, and it has the potential to become a game-changer in the treatment of this condition.